1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Psoriasis - Pipeline Insight, 2021

Psoriasis - Pipeline Insight, 2021

  • May 2021
  • 200 pages
  • ID: 6089311
  • Format: PDF
  • Delve Insight


Table of Contents

“Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Psoriasis Understanding

Psoriasis: Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors (Rendon & Schäkel, 2019). It is a non-contagious dermatosis disease affecting almost 2% of the world population. It can be observed in the form of recurring red and scaly skin plaques that can be prominently differentiated from the normal adjacent skin. The physical and psychological impact of psoriasis can be well-compared with those of diabetes, depression, heart disease and cancer. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (<2%), moderate (2–10%), and severe (>10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions.

"Psoriasis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.

Psoriasis Emerging Drugs Chapters
This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriasis Emerging Drugs
• Bimekizumab: UCB
Bimekizumab (formerly UCB4940) is a novel humanized monoclonal antibody of the immunoglobulin G1 isotype, rationally designed to be able to bind at a similar site on both proinflammatory cytokine interleukin (IL)-17A and IL-17F, conveying dual inhibition of both isoforms. It is currently in preregistration stage for the treatment of Plaque psoriasis.

• ABP 654: Amgen
ABP 654 (ustekinumab) is a biosimilar candidate to reference product STELARA. It is a monoclonal antibody that inhibits IL-12 and IL-23. Amgen is evaluating ABP 654 in Phase III clinical studies for the treatment of Inflammation (Plaque psoriasis).

• MP1032: MetrioPharm
MP1032 belongs to a new class of anti-inflammatory drugs that act as potent ROS scavengers. A unique feature of this compound class is that the scavenging activity is dynamically regulated by an intracellular feedback loop. Scavenging activity increases with increased inflammatory activation of innate immune cells and ceases at physiological, non-inflammatory activation states. It is currently in phase 2 of development stage for the treatment of Plaque psoriasis.

• Rimegepant: Biohaven Pharmaceuticals
Biohaven’s Nurtec ODT (rimegepant) Received FDA Approval in February 2020. Nurtec ODT is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT) for the acute treatment of migraine, and the only oral CGRP receptor antagonist with product label claims including return to normal functioning and sustained durability of efficacy up to 48 hours after a single dose. It is currently in phase 2 of development stage for the treatment of Plaque psoriasis.

• JTE-451: Akros Pharma
JTE 451 is a small molecule antagonists for the orphan nuclear receptor ROR? (nuclear receptor subfamily 1 group F member 3 antagonist), being developed by Japan Tobacco, as an oral formulation for the treatment of autoimmune and allergic disorders.

• GR-MD-02: Galectin Therapeutics
GR-MD-02 (belapectin) is an inhibitor of galectin. It binds to galectin-3 proteins and disrupts its function. Belapectin is the first drug in a large, randomized clinical trial to demonstrate a clinically meaningful improvement in portal hypertension or liver biopsy in patients with NASH cirrhosis without varices.

• ESR-114: Escalier Biosciences
ESR-114 topical gel is a selective, potent inhibitor of ROR?t designed to have its pharmacological activity targeted to the skin with minimal systemic absorption. ESR-114 topical gel is currently being evaluated to determine if it may reduce or treat the clinical manifestations of psoriasis. It is currently in phase 1/2 of development stage for the treatment of Plaque psoriasis.

Further product details are provided in the report……..

Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Psoriasis
There are approx. 100+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, UCB.

• Phases
This report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intramuscular
• Transdermal
• Topical.
• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.

Psoriasis Report Insights
• Psoriasis Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriasis Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Psoriasis drugs?
• How many Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Arcutis Biotherapeutics
• Sinocelltech Ltd.
• FYB202 GmbH & Co. KG
• Celltrion
• Coherus BioSciences
• Janssen Pharmaceuticals
• Can-Fite Biopharma
• Arcutis Biotherapeutics, Inc.
• Amgen
• GlaxoSmithKline
• Galectin Therapeutics Inc.
• Evelo Biosciences, Inc.
• Galderma R&D
• BioMimetix JV, LLC
• Boehringer Ingelheim
• Aurigene Discovery Technologies Limited
• AnaptysBio, Inc.
• AmDerma
• Akeso
• Affibody
• Menlo Therapeutics Inc.
• Aristea Therapeutics
• UNION Therapeutics
• MetrioPharm AG
• Provectus Pharmaceuticals
• Sienna Biopharmaceuticals
• Santalis Pharmaceuticals
• Atridia Pty Ltd.
• Dr. Reddy’s Laboratories Limited
• Galderma R&D
• AB Science
• Lycera Corp.
• LEO Pharma
• Kadmon Corporation, LLC
• Akros Pharma Inc.
• Athenex
• DelArrivo
• Theramab LLC
• AbbVie
• AstraZeneca
• Immunic
• Bio-Thera Solutions
• CSL Behring
• Palobiofarma
• SFA Therapeutics
• NeuClone
• Galapagos NV
• Boston Pharmaceuticals
• Cellenkos
• Sareum
• Temisis Therapeutics
• Dice Molecules
• Aclaris Pharma
• Midatech Pharma
• Xbrane Biopharma

Key Products
• Roflumilast
• SCT630
• FYB202
• CT-P43
• CHS-1420
• Guselkumab
• Piclidenoson
• ARQ-154
• ABP 654
• GSK2982772
• GR-MD-02
• EDP1815
• CD10367
• BMX-010
• BI 730357
• AUR 101
• AM001
• AK101
• ABY-035
• Serlopitant
• RIST4721
• UNI-50001
• MP1032
• UHE-105
• Topical Rose Bengal
• SNA-120
• SAN021
• SHR-1314
• PPC-06
• PF-07038124
• NP000888
• Masitinib
• LYC-30937-EC
• LEO 22811
• KD025
• JTE-451
• Tirbanibulin
• DLX105-DMP
• TAB08
• ABBV-157
• AZD0284
• AK111
• IMU 935
• BAT2206
• CSL324
• PBF-1650
• SFA 002
• NeuLara
• GLPG3970
• BOS-475
• CK 0801
• SDC 1801
• TEM1657
• MTX114
• ATI-2138
• Xcimbane

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on